BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$7.61
arrow_downward
-0.91%(-0.070) 1D
$7.61
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$7.67
High
$7.75
Low
$7.49
Mkt. cap
1.96B
Avg. vol.
5.39M
Volume
2.32M
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.42
Beta
0.55
Shares outstanding
257.30M
No. of employees
435
Open
$7.67
High
$7.75
Low
$7.49
Mkt. cap
1.96B
Avg. vol.
5.39M
Volume
2.32M
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.42
Beta
0.55
Shares outstanding
257.30M
No. of employees
435
News stories
From web sources and news partners
Investing.com
·
21 hours ago
BioCryst presents real-world data on ORLADEYO at ACAAI meeting
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorHealth Care
IndustryBiotechnology
Websitebiocryst.com